Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

IMGN Stock - ImmunoGen Stock Trading


home / stock / imgn

IMGN IMGN Quote IMGN Short IMGN News IMGN Articles IMGN Message Board

MWN AI Summary *

ImmunoGen Inc. (NASDAQ: IMGN) is a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) focused on treating cancer. The company is primarily engaged in the development of targeted therapies designed to improve the survival and quality of life for patients suffering from hematologic (blood) malignancies and solid tumors. ImmunoGen’s proprietary technology platform combines potent cytotoxic agents with monoclonal antibodies that selectively deliver these drugs to cancer cells, sparing healthy tissue in the process.

As of late 2023, ImmunoGen's lead product candidate, Mirvetuximab Soravtansine (brand name: Elahere), is a noteworthy ADC aimed at treating folate receptor alpha (FR?) expressing ovarian cancer. The FDA granted accelerated approval for Elahere in late 2022, based on data demonstrating improved outcomes in patients with platinum-resistant ovarian cancer who overexpress FR?. The therapy has shown promise in clinical trials, and its success marks a significant advancement for ImmunoGen, enhancing its reputation in the oncology field.

Additionally, ImmunoGen is advancing other development candidates, including programs targeting various cancers such as breast and lung cancer. The company aims to expand its therapeutic pipeline while focusing on the ongoing development of its ADC platform to create more effective treatments.

Financially, ImmunoGen has attracted interest from investors due to its market potential, especially as it continues to progress in clinical trials and expand its partnerships. The company’s focus on innovative cancer therapies aligns with the growing demand for targeted cancer treatments, making it a relevant player within the biopharmaceutical sector.

Overall, ImmunoGen represents a promising investment opportunity for those interested in biotechnology, particularly in the oncology space, with its innovative technologies and commitment to improving patient outcomes.

MWN AI Analysis *

As of October 2023, ImmunoGen Inc. (NASDAQ: IMGN) has positioned itself as a notable player in the oncology space, particularly with its focus on antibody-drug conjugates (ADCs). With the recent advancements in its clinical pipeline, the company appears to be on a path of potential growth that investors should monitor closely.

ImmunoGen's lead candidate, mirvetuximab soravtansine, is being evaluated for the treatment of folate receptor alpha-positive ovarian cancer. The promising interim results from ongoing clinical trials have gained attention and could lead to regulatory approval in the near future. Additionally, its collaboration with major pharmaceutical companies for developing and commercializing novel therapies enhances its credibility and market presence.

From a financial perspective, ImmunoGen has made strategic decisions to bolster its cash reserves and funding capabilities, evident from its recent capital raises. This positions the company well to sustain its research and development activities without diluting shareholder value excessively. However, it’s crucial for potential investors to remain vigilant about the company's burn rate and upcoming financial obligations.

Moreover, while the biotechnology sector is inherently volatile, the current market sentiment suggests room for upside if ImmunoGen's clinical trials continue to yield positive outcomes. Analysts have highlighted the stock as a potential buy given its trailing losses alleviated by upcoming catalysts such as FDA decisions and additional clinical data releases.

In conclusion, while investing in ImmunoGen involves risks typical of early-stage biotech firms, the company's strong pipeline and strategic collaborations present a compelling case for investment. A cautious yet optimistic approach is advisable, with close monitoring of clinical results and market conditions to maximize potential returns.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | ImmunoGen Inc. (NASDAQ:IMGN)

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

Quote | ImmunoGen Inc. (NASDAQ:IMGN)

Last:$31.23
Change Percent: 0.0%
Open:$0
Close:$31.23
High:$0
Low:$0
Volume:538
Last Trade Date Time:12/31/1969 07:00:00 pm

News | ImmunoGen Inc. (NASDAQ:IMGN)

  • Expected US Company Earnings on Wednesday, March 6th, 2024

    Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

    • March 06, 2024 06:01:03 am

    • |
    • US Earnings Reports
    • |
      • IMGN Stock
      • IMGN Quote
      • IMGN Short
      • IMGN News
      • IMGN Articles
      • IMGN Message Board
  • AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals

    2024-02-21 13:26:32 ET More on AbbVie AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq AbbVie names Robert A. Michael as CEO and Richard A. Gonzalez...

    • February 21, 2024 01:26:32 pm

    • |
    • SeekingAlpha
    • |
      • IMGN Stock
      • IMGN Quote
      • IMGN Short
      • IMGN News
      • IMGN Articles
      • IMGN Message Board

Message Board Posts | ImmunoGen Inc. (NASDAQ:IMGN)

Subject By Source When
znewcar1: $IMGN 135% v105M c12.26 f226,070M Hod13.31 Flushed 10.36 then pushed back strong aft znewcar1 investorshangout 05/04/2023 3:36:26 AM
whytestocks: $IMGN News Article - Why ImmunoGen Stock Is Soaring Wednesday whytestocks investorshangout 05/03/2023 4:15:48 PM
One key data point from the trial was vinmantoo investorshub 05/03/2023 4:11:57 PM
Here is the MIRASOL data which shows a vinmantoo investorshub 05/03/2023 3:35:26 PM
$IMGN: I concur; might run NOW, since most Invest-in-America investorshub 05/03/2023 3:34:05 PM

MWN AI FAQ **

What recent developments in clinical trials have influenced the stock performance of ImmunoGen Inc. (NASDAQ: IMGN)?

Recent positive phase 2 trial results for ImmunoGen's drug, mirvetuximab soravtansine, in ovarian cancer have boosted investor confidence and contributed to a rise in the stock performance of ImmunoGen Inc. (NASDAQ: IMGN).

How does ImmunoGen Inc. (NASDAQ: IMGN) plan to enhance its pipeline with upcoming drug candidates?

ImmunoGen Inc. plans to enhance its pipeline by advancing its innovative antibody-drug conjugates (ADCs) and exploring new therapeutic combinations to address unmet medical needs and improve patient outcomes.

What are the key risks associated with investing in ImmunoGen Inc. (NASDAQ: IMGN) that potential investors should consider?

Key risks associated with investing in ImmunoGen Inc. (NASDAQ: IMGN) include potential clinical trial failures, reliance on a limited pipeline of products, high competition in the oncology space, regulatory hurdles, and volatility in stock performance related to biotech sector trends.

How does ImmunoGen Inc. (NASDAQ: IMGN) compare to its peers in the biotech sector regarding innovation and market potential?

ImmunoGen Inc. (NASDAQ: IMGN) distinguishes itself in the biotech sector through its innovative antibody-drug conjugate technology, targeting solid tumors with significant market potential, yet faces competition from other biotech firms advancing similar therapeutic approaches.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get IMGN Alerts

News, Short Squeeze, Breakout and More Instantly...

ImmunoGen Inc. Company Name:

IMGN Stock Symbol:

NASDAQ Market:

0.0% G/L:

$31.23 Last:

538 Volume:

$0 Open:

$31.23 Close:

ImmunoGen Inc. Website:

ImmunoGen Inc. Logo

Ad

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
RECENT IMGN NEWS
  • IMGN - Expected US Company Earnings on Wednesday, March 6th, 2024

    Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

  • IMGN - AbbVie Completes Acquisition of ImmunoGen

    AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...

  • IMGN - (IMGN) Investment Analysis

    2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Important Investor News Alert (NASDAQ: CVKD)

 Logo

  • CVKD - Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

    LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per ev...

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get IMGN Alerts

Get IMGN Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1